UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000031330
Receipt number R000035757
Scientific Title Exploratory study of clinical effectiveness and safety of TJ-116 bukuryoingohangekobokuto for anxiety and postoperative water brash in esophageal cancer patients
Date of disclosure of the study information 2018/02/16
Last modified on 2018/02/16 10:00:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Exploratory study of clinical effectiveness and safety of TJ-116 bukuryoingohangekobokuto for anxiety and postoperative water brash in esophageal cancer patients

Acronym

Investigation of TJ-116 bukuryoingohangekobokuto for postoperative water brash in esophageal cancer.

Scientific Title

Exploratory study of clinical effectiveness and safety of TJ-116 bukuryoingohangekobokuto for anxiety and postoperative water brash in esophageal cancer patients

Scientific Title:Acronym

Investigation of TJ-116 bukuryoingohangekobokuto for postoperative water brash in esophageal cancer.

Region

Japan


Condition

Condition

Esophageal cancer

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

In order to examine the effectiveness and safety of TJ-116 Tsumura bukuryoingohangekobokuto for anxiety accompanying esophageal cancer and postoperative water brash, Hospital Anxiety and Depression Scale: HADS, Assessment of Swallowing Ability for Pneumonia: ASAP, Esophagus and Stomach Surgery Symptom Scale: ES4, and Videofluoroscopic examination of swallowing: VF were measured as main evaluation items.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase IV


Assessment

Primary outcomes

Symptoms of feeling, anxiety, water brash

Key secondary outcomes

1. Incidence frequency of aspiration pneumonia
2. Postoperative hospital stay
3. Abdominal gas volume
4. Inflammatory marker (IL-6,TNFa,G-CSF,WBC)
5. Chest CT
6. Nutritional status (Body weight, BMI, TSF, AMC, Grip strength,In Body Analysis, CONUT, nutrition-related markers)
7. Clinical examination


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Conventional treatment

Interventions/Control_2

In addition to conventional treatment, bukuryoingohangekobokuto is divided into 3 times 7.5 g per day (2.5 g (1 package) once a day), from 2 weeks before operation to 6 weeks after operation or until discontinuation (surgery Except that day) before meals are administered orally in principle.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients waiting for chest upper to lower
esophageal cancer radical resection
2. Pre treatment cStage:II, III, IVA (except for T4b, N3) TNM classification:T=1-4a, N=0-2, M=0(TNM-UICC 8 th edition)
3. Performance Status:0-2
4. Hospital Anxiety and Depression Scale (HADS): 8 <=
5. 20 years old and over
6. Medical examination classification:outpatient and inpatient
7. Patients who obtain document consent from the principal

Key exclusion criteria

1. Patients who have past history of abdominal surgery
2 Patients who have past history of ileus
3 Patients with concomitant inflammatory bowel disease such as ulcerative colitis and crohn disease
4. Eemergent surgery
5. Patients who took prohibited concomitant drugs 4 weeks before treatment
6. Patients who have past history of radiotherapy and radiation chemotherapy for esophageal cancer
7. Patients who have past history of allergy for other Kampo formulation(s)
8. Patients who have serious concomitant diseases
9. A woman who is pregnant, has a possibility of pregnancy, is within 28 days after birth, is breastfeeding
10. Dementia patients
11. Others, including patients who are unfit for the study as determined by the attending physician

Target sample size

24


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tadashi Ishii

Organization

Tohoku University Hospital

Division name

Department of Education and Support for Regional Medicine

Zip code


Address

1-1, seiryomachi, aobaku, sendai city, miyagi prefecture, Japan

TEL

022-717-7587

Email

t-ishi23@med.tohoku.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Shin Takayama

Organization

Tohoku University Hospital

Division name

Department of Education and Support for Regional Medicine. Department of Kampo medicine

Zip code


Address

1-1, seiryomachi, aobaku, sendai city, miyagi prefecture, Japan

TEL

022-717-7507

Homepage URL


Email

takayama@med.tohoku.ac.jp


Sponsor or person

Institute

Department of Education and Support for Regional Medicine.
Department of Kampo medicine

Institute

Department

Personal name



Funding Source

Organization

TSUMUA & Co.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東北大学病院(宮城県)


Other administrative information

Date of disclosure of the study information

2018 Year 02 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2018 Year 02 Month 20 Day

Date of IRB


Anticipated trial start date

2018 Year 03 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 02 Month 16 Day

Last modified on

2018 Year 02 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035757


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name